Stephan Bart
Overview
Explore the profile of Stephan Bart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
382
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Comeaux C, Bart S, Bastian A, Klyashtornyy V, De Paepe E, Omoruyi E, et al.
J Infect Dis
. 2023 Jul;
229(1):19-29.
PMID: 37433021
Background: Ad26.RSV.preF is an adenovirus serotype 26 vector-based respiratory syncytial virus (RSV) vaccine encoding a prefusion conformation-stabilized RSV fusion protein (preF) that demonstrated robust humoral and cellular immunogenicity and showed...
2.
Shaw C, August A, Bart S, Booth P, Knightly C, Brasel T, et al.
Vaccine
. 2023 May;
41(26):3898-3906.
PMID: 37210308
Background: Chikungunya, a mosquito-borne viral disease caused by the chikungunya virus (CHIKV), causes a significant global health burden, and there is currently no approved vaccine to prevent chikungunya disease. In...
3.
Falsey A, Williams K, Gymnopoulou E, Bart S, Ervin J, Bastian A, et al.
N Engl J Med
. 2023 Feb;
388(7):609-620.
PMID: 36791161
Background: Respiratory syncytial virus (RSV) can cause serious lower respiratory tract disease in older adults, but no licensed RSV vaccine currently exists. An adenovirus serotype 26 RSV vector encoding a...
4.
Bockstal V, Shukarev G, McLean C, Goldstein N, Bart S, Gaddah A, et al.
PLoS One
. 2022 Oct;
17(10):e0274906.
PMID: 36197845
Background: Though clinically similar, Ebola virus disease and Marburg virus disease are caused by different viruses. Of the 30 documented outbreaks of these diseases in sub-Saharan Africa, eight were major...
5.
Bockstal V, Gaddah A, Goldstein N, Shukarev G, Bart S, Luhn K, et al.
NPJ Vaccines
. 2021 Dec;
6(1):157.
PMID: 34930928
Two phase 3 clinical studies were conducted in the USA to bridge across different Ad26.ZEBOV manufacturing processes and sites, and to evaluate the immunogenicity of different dose levels of Ad26.ZEBOV...
6.
Tasker S, Wight ORourke A, Suyundikov A, Booth P, Bart S, Krishnan V, et al.
Vaccines (Basel)
. 2021 Apr;
9(3).
PMID: 33807649
Annual influenza vaccination greatly reduces morbidity and mortality, but effectiveness remains sub-optimal. Weaknesses of current vaccines include low effectiveness against mismatched strains, lack of mucosal and other effective tissue-resident immune...
7.
Goldstein N, Bockstal V, Bart S, Luhn K, Robinson C, Gaddah A, et al.
J Infect Dis
. 2020 Sep;
226(4):595-607.
PMID: 32939546
Background: This phase 1 placebo-controlled study assessed the safety and immunogenicity of 2-dose regimens of Ad26.ZEBOV (adenovirus serotype 26 [Ad26]) and MVA-BN-Filo (modified vaccinia Ankara [MVA]) vaccines with booster vaccination...
8.
Peters E, Herrmann E, Smith C, Wilhelm J, Koszowski B, Halquist M, et al.
Exp Clin Psychopharmacol
. 2020 May;
29(4):345-354.
PMID: 32463281
Co-users of cannabis and tobacco frequently use cannabis, then tobacco cigarettes, in a sequential pattern within an occasion, that is, they "chase" smoked cannabis with a tobacco cigarette. The objective...
9.
Cartee R, Thanawastien A, Griffin Iv T, Mekalanos J, Bart S, Killeen K
PLoS Negl Trop Dis
. 2020 Jan;
14(1):e0007912.
PMID: 31905228
Background: Typhoid fever remains a significant cause of morbidity and mortality in developing countries especially in children ≤5 years old. Although the widely available unconjugated Vi polysaccharide vaccines are efficacious,...
10.
Barouch D, Tomaka F, Wegmann F, Stieh D, Alter G, Robb M, et al.
Lancet
. 2018 Jul;
392(10143):232-243.
PMID: 30047376
Background: More than 1·8 million new cases of HIV-1 infection were diagnosed worldwide in 2016. No licensed prophylactic HIV-1 vaccine exists. A major limitation to date has been the lack...